Skip to main content
Publications
Shah R, Girard N, Nagar S, Griesinger F, Roeper J, Davis KL, Bakker NA, Thakrar B, Taylor A, Feliciano J. Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI). Poster presented at the ESMO 2019 Congress; September 27, 2019. Barcelona, Spain.
Mazieres J, Ahn MJ, Chouaid C, Kron A, Wolf J, Goyal RK, Davis KL, Perrinjaquet M, Pham T, Knoll S. Genetic testing patterns, treatment characteristics, and overall survival in ALK-positive metastatic NSCLC patients treated with Ceritinib. Poster presented at the 2019 World Conference on Lung Cancer; September 8, 2019. Barcelona, Spain.
Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447
Horn L, Bauml J, Forde PM, Davis KL, Myall NJ, Sasane M, Dalal A, Culver K, Wozniak AJ, Baik CS, Mutebi A, Zhang P, Wakelee HA, Johnson BE. Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. Lung Cancer. 2019 Feb;128(2019):74-90. doi: 10.1016/j.lungcan.2018.12.003
Blonde L, Raccah D, Lew E, Meyers J, Nikonova E, Ajmera M, Davis KL, Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin. Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Nagar SP, Rane PP, Fox KM, Meyers J, Davis K, Beaubrun A, Inomata H, Qian Y, Kajinami K. Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J. 2018 Mar 23;82(4):1008-16. doi: 10.1253/circj.CJ-17-0811
Blonde L, Lew E, Raccah D, Meyers J, Ajmera M, Davis K, Bertolini M, Guerci B. A real-world comparison of outcomes in patients receiving three oral antidiabetic therapies, GLP-1, or basal insulin: an analysis of electronic medical record data. Poster presented at the American Diabetes Association 77th Scientific Sessions; June 10, 2017. San Diego, CA.
Nagar SP, Fox KM, Rane PP, Beaubrun A, Qian Y, Inomata H, Davis KL, Meyers J, Kajinami K. Incidence of cardiovascular events among secondary prevention patients treated with statins or ezetimibe in Japan. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A261.
Kajinami K, Nagar SP, Meyers J, Rane PP, Davis K, Fox KM, Beaubrun A, Inomata H, Qian Y. Treatment utilization patterns and possible statin intolerance among high-risk patients in a real-world Japanese population. Poster presented at the 81st Annual Scientific Meeting of the Japanese Circulation Society; March 19, 2017. Kanazawa, Japan.
Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.
Goyal RK, Carter GC, Nagar SP, Smyth EN, Price GL, Huang Y-J, Bromund JL, Li L, Schilder JM, Davis KL, Kaye JA. Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.
Blonde L, Kitio-Dschassi B, Guerci B, Meyers J, Berria R, Ajmera M, Nikonova E, Davis K, Bertolini M, Raccah D. A real-world comparison of longitudinal HbA1c and health care costs in patients receiving two oral antidiabetic therapies, GLP-1RAs, or basal insulin. Presented at the 76th American Diabetes Association (ADA) Scientifc Sessions; June 13, 2016. New Orleans, LA.
Blonde L, Kitio-Dschassi B, Guerci B, Meyers J, Berria R, Ajmera M, Nikonova E, Davis K, Bertolini M, Raccah D. A real-world comparison of outcomes in patients receiving two oral antidiabetic therapies, GLP-1RAs, or basal insulin: an analysis of electronic medical record data. Poster presented at the 76th American Diabetes Association (ADA) Scientifc Sessions; June 12, 2016. New Orleans, LA.
Ajmera MR, Davis KL, Price G, Li L, Huang YJ, Price GL, Goyal RK, John WJ, Cuyun Carter G, Kaye JA, Boye ME. Economic outcomes associated with tumor histology among elderly patients with metastatic non–small cell lung cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A165.